Neuronetics Receives the US FDA’s 510(k) Clearance of MT Cap Technology to Treat Obsessive-Compulsive Disorder
Shots:
- The company received FDA 510(k) clearance to obsessive-compulsive disorder (OCD) Motor Threshold (MT) Cap tech for NeuroStar advanced therapy for mental health. The unique design & functionality of the OCD MT Cap will enable clinicians to optimize treatment efficiency
- The technology simplifies the initial placement of a NeuroStar coil. It provides a consistent starting location and a step-by-step process to map a patient’s motor cortex while MT cap features compatibility with Fast MT, providing up to 40% time savings for clinicians and patients in the initial visit
- The OCT MT Cap will become available starting this month at select sites with nationwide availability expected in Q4’23
Ref: Neuronetics | Image: Neuronetics
Related News:- Avation Medical Receives the US FDA’s 510(k) Clearance of Vivally System for Urinary Urgency and Urge Urinary Incontinence
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
